参一胶囊对晚期NSCLC 维持治疗的临床研究

目的:探讨晚期非小细胞肺癌(NSCLC)患者化疗获益后采用参一胶囊维持治疗的临床疗效。方法:选择2010年11月到2014年11月在我院经一线化疗后疗效评价无病情进展的120例晚期NSCLC患者,随机分为对照组(n=60)和实验组(n=60)。对照组仅接受定期随访观察,实验组采用参一胶囊维持治疗,比较两组患者治疗后的临床疗效、治疗前后免疫功能、生活质量的变化及不良反应的发生情况。结果:实验组患者的疾病控制率(DCR)明显高于对照组(P0.05)。治疗后,两组患者各免疫功能检测指标均低于治疗前,且实验组明显大于对照组(P0.05)。治疗后,实验组KPS评分提高率明显高于对照组(P0.05)。整个维持治疗过程中无治疗相关性死亡。结论:晚期NSCLC患者在化疗后采用参一胶囊维持治疗,可显著提高患者免疫功能、改善生活质量,且安全性良好,疗效显著,值得在临床上推广应用。

Clinical Research of Ginsenoside Rg3 in the Maintenance Treatment of Advanced NSCLC

Objective:To investigate the clinical efficacy of ginsenoside Rg3 in maintenance treatment of patients with advanced non-small cell lung cancer(NSCLC) after chemotherapy.Methods:A total of 120 patients with advanced NSCLC, who were treated with the first-line chemotherapy and without progression disease in Affiliated Hospital of Chengdu University of Traditional Chinese from November 2010 to November 2014, were selected and randomly divided into experiment group (n=60) and control group (n=60). The control group was only regularly followed up and observed, while the experiment group was maintained with ginsenoside Rg3. Then the clinical efficacy, the changes of immune indexes and the quality of life before and after treatment and the incidence of adverse reactions in the two groups were compared.Results:The disease control rate (DCR) of experimental group was obviously higher than that of control group (P<0.05). The immune indexes of two groups after treatment were lower than before treatment, meanwhile, the indexes of experimental group were significantly higher than those of control group (P<0.05). The improvement rate of KPS score in the experimental group after treatment was significantly higher than that in the control group (P<0.05). There was no treatment-related death during the whole maintenance treatment.Conclusion:Using ginsenoside Rg3 in the maintenance treatment of patients with advanced NSCLC after chemotherapy can improve the immune function and increase the quality of life, with good safety and efficacy,which is worthy of clinical promotion.